Autologous tumor immune cells assisted interventional therapy in advanced primary liver cancer
10.11659/jjssx.01E016048
- VernacularTitle:自体肿瘤免疫细胞辅助介入治疗中晚期原发性肝癌
- Author:
Shiwei YU
;
Houbin SUN
;
Linan YIN
;
Yingwen HOU
;
Ruibao LIU
- Publication Type:Journal Article
- Keywords:
tumor immune cell;
primary liver cancer;
liver function;
tumor marker
- From:
Journal of Regional Anatomy and Operative Surgery
2016;25(10):762-764,765
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical effects of autologous tumor immune cells (DC-CIK)assisted interventional therapy in the treatment of advanced primary liver cancer.Methods Totally 76 patients with advanced primary liver cancer were divided into 2 groups with 38 cases in each group by random number table method.The control group were merely treated with interventional therapy while the ob-servation group were treated with autologous DC-CIK cell assisted interventional therapy.The short-term curative effect,adverse reactions,liver function indexes before and after treatment,alpha fetal protein (AFP)and changes of immune function were compared between the 2 groups. Results There was no statistically significant difference in short-term curative effect and incidence of adverse reactions between the 2 groups (P >0.05).After treatment,the levels of AST,ALT and AFP in the observation group [(30.4 ±6.0)u/L,(45.2 ±3.8)u/L,(168.5 ± 49.3)mg/L]were significantly lower than those in the control group [(65.1 ±6.3)u/L,(61.8 ±5.3)u/L,(315.2 ±39.5)mg/L],and the differences were statistically significant (P <0.05).After treatment,CD3 +,CD4 + and CD4 +/CD8 + in the observation group were significantly higher than those in the control group (P <0.05).Conclusion Autologous DC-CIK cell assisted interventional therapy can sig-nificantly improve the liver function of patients with advanced primary liver cancer,and it can reduce the level of tumor marker AFP and sig-nificantly improve the immune function of patients.
